These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 16537687)

  • 21. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and limits of somatostatin analogs.
    Petersenn S
    J Endocrinol Invest; 2005; 28(11 Suppl International):53-7. PubMed ID: 16625846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.
    Cozzi R; Barausse M; Sberna M; Lodrini A; Franzini A; Lasio G; Attanasio R
    Pituitary; 2000 Dec; 3(4):231-8. PubMed ID: 11788011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly.
    Bhayana S; Booth GL; Asa SL; Kovacs K; Ezzat S
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6290-5. PubMed ID: 16118335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly.
    Colao A; Auriemma RS; Rebora A; Galdiero M; Resmini E; Minuto F; Lombardi G; Pivonello R; Ferone D
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):237-45. PubMed ID: 19094074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
    Tutuncu Y; Berker D; Isik S; Ozuguz U; Akbaba G; Kucukler FK; Aydin Y; Guler S
    Pituitary; 2012 Sep; 15(3):398-404. PubMed ID: 21863263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly.
    Theodoropoulou M; Tichomirowa MA; Sievers C; Yassouridis A; Arzberger T; Hougrand O; Deprez M; Daly AF; Petrossians P; Pagotto U; Beckers A; Stalla GK
    Int J Cancer; 2009 Nov; 125(9):2122-6. PubMed ID: 19637311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
    Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
    Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
    Baldelli R; Colao A; Razzore P; Jaffrain-Rea ML; Marzullo P; Ciccarelli E; Ferretti E; Ferone D; Gaia D; Camanni F; Lombardi G; Tamburrano G
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4099-103. PubMed ID: 11095439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
    Casarini AP; Pinto EM; Jallad RS; Giorgi RR; Giannella-Neto D; Bronstein MD
    J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.
    Attanasio R; Barausse M; Cozzi R
    J Endocrinol Invest; 2001 Apr; 24(4):209-16. PubMed ID: 11383906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study.
    Razzore P; Colao A; Baldelli R; Gaia D; Marzullo P; Ferretti E; Ferone D; Jaffrain-Rea ML; Tamburrano G; Lombardi G; Camanni F; Ciccarelli E
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):159-64. PubMed ID: 10468985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
    Cannavò S; Squadrito S; Curtò L; Almoto B; Trimarchi F
    Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
    Ayuk J; Stewart SE; Stewart PM; Sheppard MC
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4142-6. PubMed ID: 12213862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.